BUKWANG PHARMACEUTICAL IND CO.,LTD
Financials
Valuation Metrics
BUKWANG PHARMACEUTICAL IND CO.,LTD's Market Cap is ₩4228B. At end of 2025 it was ₩3734B. Ranked #497 of 2,436 in KR market (top 20%), #310 of 787 on KOSPI (top 39%), #57 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 422.78B KRW | KR#497/2,436 Sec#57/234 |
| Revenue | 200.68B KRW | KR#1,012/2,436 Sec#58/234 |
| Net Income | 13.71B KRW | KR#788/2,436 Sec#52/234 |
| Total Assets | 469.60B KRW | KR#770/2,436 Sec#45/234 |
| Net Assets | 340.93B KRW | KR#648/2,436 Sec#42/234 |
| Employees | 582 | KR#425/2,436 Sec#37/234 |
| Value | ||
| P/E | 30.85x | KR#1,261/2,436 Sec#77/234 |
| P/B | 1.24x | KR#1,670/2,436 Sec#114/234 |
| PEG | 0.05x | KR#277/2,436 Sec#13/234 |
| P/S | 2.11x | KR#1,853/2,436 Sec#105/234 |
| EV/EBITDA | 31.67x | KR#1,203/2,436 Sec#80/234 |
| FCF Yield | 3.36% | KR#978/2,436 Sec#60/234 |
| Profitability | ||
| ROE | 4.02% | KR#1,113/2,436 Sec#81/234 |
| ROA | 2.92% | KR#965/2,436 Sec#83/234 |
| Op. Margin | 6.11% | KR#788/2,436 Sec#65/234 |
| Revenue Growth | -0.06% | KR#1,444/2,436 Sec#138/234 |
| Earnings Growth | 573.06% | KR#97/2,436 Sec#5/234 |
| Financial Health | ||
| Debt Ratio | 137.74% | KR#991/2,436 Sec#115/234 |
| Total Debt | 79.68B KRW | KR#802/2,436 Sec#54/234 |
| FCF | 14.21B KRW | KR#616/2,436 Sec#33/234 |
| Cash | 114.42B KRW | KR#422/2,436 Sec#19/234 |
| Current Ratio | 2.55x | KR#733/2,436 Sec#91/234 |
| Net Debt/EBITDA | -2.84x | KR#210/2,436 Sec#9/234 |
| Dividend | ||
| Div. Yield | 3.11% | KR#653/2,436 Sec#32/234 |
| Performance | ||
| 1Y Return | 30.24% | KR#341/2,436 Sec#31/234 |
| 1M Return | 3.00% | KR#597/2,436 Sec#50/234 |
| From 52W High | -56.67% | KR#1,546/2,436 Sec#132/234 |
| 1Y MDD | -61.82% | KR#1,514/2,436 Sec#120/234 |
| Trading | ||
| Volume | 460,577 shares | KR#298/2,436 Sec#34/234 |
| Foreign Own. | 7.70% | KR#583/2,436 Sec#54/234 |
| Per Share | ||
| EPS | 153 KRW | KR#1,283/2,436 Sec#90/234 |
| BPS | 3,380 KRW | KR#1,730/2,436 Sec#131/234 |
Company Info
Bugwang Pharm, established in 1960 for the purpose of manufacturing and selling pharmaceuticals, was listed on the Securities Market in 1988. The company holds four unlisted subsidiaries, including Denmark-based Contera Pharma A/S, Bugwang Medica Co., Ltd., JaguAHR Therapeutics, and ProteKt Therapeutics. It engages in the manufacturing and sales of pharmaceuticals and quasi-drugs, with major products including Dexid, Ferroba, Legalon, Latuda, and Tasenol. Bugwang Pharm is headquartered in Dongjak-gu, Seoul.